LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis (Équipe Housset)

19 - Décembre - 2018

Thierry Poynard, Valentina Peta, Olivier Deckmyn, Mona Munteanu, Joseph Moussalli, Yen Ngo, Marika Rudler, Pascal Lebray, Raluca Pais, Luminita Bonyhay, Frederic Charlotte, Vincent Thibault, Laetitia Fartoux, Olivier Lucidarme, Daniel Eyraud, Olivier Scatton, Eric Savier, Marc Antoine Valantin, An Ngo, Fabienne Drane, Olivier Rosmorduc, Françoise Imbert‐Bismut, Chantal Housset, Dominique Thabut, Vlad Ratziu, the HECAM‐FibroFrance Group

Aliment Pharmacol Ther. 2019;49(3):308-20

Background: No blood test has been shown to be effective in the prediction of primary liver cancer in patients without cirrhosis. AIM: To construct and internally validate two sequential tests for early prediction of liver cancer. These tests enable an algorithm which could improve the performance of the standard surveillance protocol recommended (imaging with or without AFP), limited to patients with cirrhosis.

Methods: We performed a retrospective analysis in prospectively collected specimens from an ongoing cohort. We designed an early sensitive high-risk test (LCR1) that combined (using Cox model) hepatoprotective proteins (apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a marker of fibrosis (alpha2-macroglobulin). To increase the specificity, we then combined (LCR2) these components with alpha-fetoprotein.

Results: A total of 9892 patients, 85.9% without cirrhosis, were followed up for 5.9 years [IQR: 4.3-9.4]. LCR1 and LCR2 time-dependent AUROCs were not different in construction and validation randomised subsets. Among 2027 patients with high-LCR1 then high-LCR2, 167 cancers (113 with cirrhosis, 54 without cirrhosis) were detected, that is 12 patients needed to screen one cancer. The negative predictive value was 99.5% (95% CI 99.0-99.7) in the 2026 not screened patients (11 cancers without cirrhosis) higher than the standard surveillance, which detected 113 cancers in 755 patients screened, that is seven patients needed to screen one cancer, but with a lower negative predictive value 98.0% (97.5-98.5; Z = 4.3; P < 0.001) in 3298 not screened patients (42 cancers without cirrhosis).

Conclusions: In patients with chronic liver disease the LCR1 and LCR2 tests identify those with a high risk of liver cancer, including in those without cirrhosis. NCT01927133.


2018 Aliment Pharmacol Ther - Poynard (fig).jpg

Survival without primary liver cancer according to LCR1 and LCR2 cut-offs. A, 10-year survival without primary liver cancer according to low (<0.015 optimal cut-off) LCR1, vs high (≥0.015 optimal cut-off) LCR1. Among patients without cirrhosis with low-LCR1, 13 cancer occurred, representing a 99.6% (95% CI 99.3-99.8) 10 year survival without cancer, vs 61 with high LCR1, survival without cancer = 95.9% (95% CI 94.8-97.0) (P < 0.001). B, Five-year survival without primary liver cancer according to low (<0.044 optimal cut-off) LCR2, vs high (≥0.044 optimal cut-off) LCR2. Among patients selected by LCR1 (without cirrhosis or with cirrhosis) but a low-LCR2 (<0.044), at 5 years 23 PLC occurred, a survival without cancer = 98.4% (65% CI 97.7-99.0), vs 69 with high LCR2 (≥0.044) out of 681 a survival withoiut cancer = 87.3% (95% CI 84.5-90.2) (P < 0.001)

Hôpital St-Antoine

Bâtiment Kourilsky
34 rue Crozatier
75012 PARIS

Sorbonne Université
27 rue Chaligny
75012 PARIS

Ce site utilise des cookies et vous donne le contrôle sur ce que vous souhaitez activer Tout accepter Personnaliser